Back to Studies

P1100 / AERAS 402

A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis

Study Status

Concluded

DAIDS Number

11801

IND Number

No IND (see comment)

Study Chair

DAIDS Medical Officer

NICHD Medical Officer

Clinical Research Manager

DAIDS Clinical Representative

SC Representative

Senior Statistician